NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential
Takahiro Miyazaki(Nektar Therapeutics (United States)), Stephen K. Doberstein(Xencor (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Marlene Hennessy(Nektar Therapeutics (United States)), David V. Gauvin(MACOM (United States)), Cherie F. Ali(MACOM (United States)), Neel K. Anand(ETH Zurich), Daniel McWeeney(MACOM (United States)), Juli Evans(MACOM (United States)), Hema Gursahani(MACOM (United States)), Grace Kim(University of California, San Francisco), Timothy A. Riley(MACOM (United States)), Irene Choi(MACOM (United States)), Juergen Pfeiffer(MACOM (United States)), Jennifer A. Riggs(MACOM (United States)), Kathleen R. Gogas(MACOM (United States)), Werner Rubas(University of California, San Francisco)
Cited by 46
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
A Simple, Mild, Catalytic, Enantioselective Addition of Terminal Acetylenes to Aldehydes
|Journal of the American Chemical Society|2001|470
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403